1. Hydroxytyrosol inhibits MAO isoforms and prevents neurotoxicity inducible by MPP+ invivo.
- Author
-
Perez-Barron GA, Montes S, Rubio-Osornio M, Avila-Acevedo JG, Garcia-Jimenez S, Rios LC, and Monroy-Noyola A
- Subjects
- 1-Methyl-4-phenylpyridinium antagonists & inhibitors, Animals, Antioxidants metabolism, Catecholamines, Corpus Striatum drug effects, Dopamine metabolism, Monoamine Oxidase pharmacology, Parkinson Disease, Phenylethyl Alcohol pharmacology, Protein Isoforms metabolism, Rats, Rats, Wistar, Monoamine Oxidase metabolism, Monoamine Oxidase Inhibitors pharmacology, Phenylethyl Alcohol analogs & derivatives
- Abstract
Parkinson's disease is considered to be due to an increase in the catabolism of dopamine by the action of monoamine oxidase (MAO) enzymes which leads to an increase in reactive oxygen species (ROS) and loss of dopaminergic neurons. Here, in a model of neurotoxicity inducible by 1-methyl-4-phenylpyridinium (MPP+), we tested the effect of hydroxytyrosol (HTy), a potent antioxidant, on generation of ROS. Five minutes after a single intravenous administration of 1.5 mg/Kg of Hty, Wistar rats received an intrastriatal micro-injection of 10 micrograms of MPP+ while control animals received saline solution. Six days later, all animals were treated with apomorphine (1 mg/Kg), subcutaneously and ipsilateral rotations were assessed within an hour. Then, the rats were sacrificed, striatal tissues were removed and their catecholamines and MAO-A and B activities were quantitated. Pretreatment with HTy significantly diminished the number of ipsilateral rotations. This recovery correlated with significant preservation of striatal dopamine and significant inhibition of of the MAO activity. These results are consistent with the inhibitory effect of HTy on the MAO isoforms and form a basis for the neuroprotective mechanism of this phenylpropanoid in MPP+ induced Parkinson's disease.
- Published
- 2020
- Full Text
- View/download PDF